FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171875475> ?p ?o ?g. }

• W2171875475 endingPage "901" @default.
• W2171875475 startingPage "891" @default.
• W2171875475 abstract "Chronic obstructive pulmonary disease (COPD) is associated with eosinophilic airway inflammation in 10-20% of patients. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, depletes blood and sputum eosinophils. We aimed to establish whether benralizumab reduces acute exacerbations of COPD in patients with eosinophilia and COPD.We did this randomised, double-blind, placebo-controlled, phase 2a study between Nov 18, 2010, and July 13, 2013, at 26 sites in the UK, Poland, Germany, Canada, the USA, Denmark, and Spain. Adults aged 40-85 years, with moderate-to-severe COPD, at least one acute exacerbation of COPD, and a sputum eosinophil count of 3·0% or more within the previous year, were randomly assigned (1:1) via computer-generated permuted block randomisation (block size of four), with an interactive voice or web-response system, to receive placebo or 100 mg benralizumab subcutaneously, every 4 weeks (three doses), then every 8 weeks (five doses) over 48 weeks. Study site personnel included in study assessments, participants, and data analysts, were masked to treatment allocation. The primary endpoint was the annualised rate of acute exacerbations of COPD at week 56, defined as the number of acute exacerbations divided by total duration of person-year follow-up. Secondary and exploratory endpoints included COPD-specific Saint George's Respiratory Questionnaire (SGRQ-C), Chronic Respiratory Questionnaire self-administered standardised format (CRQ-SAS), pre-bronchodilator forced expiratory volume in 1 second (FEV1), and safety. We did a prespecified subgroup analysis by baseline blood eosinophil count. Analyses were by intention to treat and per-protocol. This trial is registered with ClinicalTrials.gov, number NCT01227278.We randomly assigned 101 patients to receive placebo (n=50) or benralizumab (n=51), of whom 88 (87%) patients completed the study. Six patients who completed the study were excluded from the per-protocol population because of major protocol violations; the per-protocol population thus included 82 patients. Benralizumab did not reduce the annualised rate of acute exacerbations of COPD compared with placebo in the per-protocol population, with rates of 0·95 (0·68-1·29; n=40) versus 0·92 (0·67-1·25; n=42). Mean pre-bronchodilator FEV1 change from baseline to week 56 was -0·06 L (SD 0·24) with placebo, and 0·13 L (0·41) with benralizumab (p=0·014). Numerical, albeit non-significant, improvement in acute exacerbations of COPD, SGRQ-C, CRQ-SAS, and FEV1 were greater in benralizumab-treated patients with baseline blood eosinophil concentrations of 200 cells per μL or more or 300 cells per μL or more. Incidence of treatment-emergent adverse events was similar between the two groups, with the most common events being respiratory disorders (31 [62%] of 50 patients given placebo vs 32 [63%] of 51 given benralizumab) and infections (28 [56%] vs 27 [53%]). A higher incidence of serious treatment-emergent adverse events were recorded in patients in the benralizumab group than in those in the placebo group (14 vs nine patients), although none of these events were considered by the investigator to be benralizumab related.Compared with placebo, benralizumab did not reduce the rate of acute exacerbations of COPD. However, the results of prespecified subgroup analysis support further investigation of benralizumab in patients with COPD and eosinophilia.MedImmune." @default.
• W2171875475 created "2016-06-24" @default.
• W2171875475 creator A5003269065 @default.
• W2171875475 creator A5021121714 @default.
• W2171875475 creator A5044664487 @default.
• W2171875475 creator A5046450175 @default.
• W2171875475 creator A5048320859 @default.
• W2171875475 creator A5048656238 @default.
• W2171875475 creator A5052241700 @default.
• W2171875475 creator A5065989521 @default.
• W2171875475 creator A5082888399 @default.
• W2171875475 date "2014-11-01" @default.
• W2171875475 modified "2023-10-14" @default.
• W2171875475 title "Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study" @default.
• W2171875475 cites W1760281680 @default.
• W2171875475 cites W1916962812 @default.
• W2171875475 cites W1972175300 @default.
• W2171875475 cites W1988758075 @default.
• W2171875475 cites W1992426791 @default.
• W2171875475 cites W1996214993 @default.
• W2171875475 cites W2001471813 @default.
• W2171875475 cites W2001965102 @default.
• W2171875475 cites W2012519534 @default.
• W2171875475 cites W2026656842 @default.
• W2171875475 cites W2033380992 @default.
• W2171875475 cites W2035374789 @default.
• W2171875475 cites W2052977441 @default.
• W2171875475 cites W2062918919 @default.
• W2171875475 cites W2065797637 @default.
• W2171875475 cites W2073959308 @default.
• W2171875475 cites W2078509571 @default.
• W2171875475 cites W2078552229 @default.
• W2171875475 cites W2085467958 @default.
• W2171875475 cites W2088797046 @default.
• W2171875475 cites W2095754126 @default.
• W2171875475 cites W2097667004 @default.
• W2171875475 cites W2103470959 @default.
• W2171875475 cites W2133986277 @default.
• W2171875475 cites W2137890862 @default.
• W2171875475 cites W2139347600 @default.
• W2171875475 cites W2142724633 @default.
• W2171875475 cites W2145466675 @default.
• W2171875475 cites W2145774897 @default.
• W2171875475 cites W2155734497 @default.
• W2171875475 cites W2155765761 @default.
• W2171875475 cites W2160220254 @default.
• W2171875475 cites W2166667839 @default.
• W2171875475 cites W2167574236 @default.
• W2171875475 cites W239161963 @default.
• W2171875475 doi "https://doi.org/10.1016/s2213-2600(14)70187-0" @default.
• W2171875475 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5082845" @default.
• W2171875475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25208464" @default.
• W2171875475 hasPublicationYear "2014" @default.
• W2171875475 type Work @default.
• W2171875475 sameAs 2171875475 @default.
• W2171875475 citedByCount "237" @default.
• W2171875475 countsByYear W21718754752014 @default.
• W2171875475 countsByYear W21718754752015 @default.
• W2171875475 countsByYear W21718754752016 @default.
• W2171875475 countsByYear W21718754752017 @default.
• W2171875475 countsByYear W21718754752018 @default.
• W2171875475 countsByYear W21718754752019 @default.
• W2171875475 countsByYear W21718754752020 @default.
• W2171875475 countsByYear W21718754752021 @default.
• W2171875475 countsByYear W21718754752022 @default.
• W2171875475 countsByYear W21718754752023 @default.
• W2171875475 crossrefType "journal-article" @default.
• W2171875475 hasAuthorship W2171875475A5003269065 @default.
• W2171875475 hasAuthorship W2171875475A5021121714 @default.
• W2171875475 hasAuthorship W2171875475A5044664487 @default.
• W2171875475 hasAuthorship W2171875475A5046450175 @default.
• W2171875475 hasAuthorship W2171875475A5048320859 @default.
• W2171875475 hasAuthorship W2171875475A5048656238 @default.
• W2171875475 hasAuthorship W2171875475A5052241700 @default.
• W2171875475 hasAuthorship W2171875475A5065989521 @default.
• W2171875475 hasAuthorship W2171875475A5082888399 @default.
• W2171875475 hasBestOaLocation W21718754752 @default.
• W2171875475 hasConcept C126322002 @default.
• W2171875475 hasConcept C142724271 @default.
• W2171875475 hasConcept C1862650 @default.
• W2171875475 hasConcept C204787440 @default.
• W2171875475 hasConcept C27081682 @default.
• W2171875475 hasConcept C2776042228 @default.
• W2171875475 hasConcept C2776301714 @default.
• W2171875475 hasConcept C2776780178 @default.
• W2171875475 hasConcept C2777014857 @default.
• W2171875475 hasConcept C2777037409 @default.
• W2171875475 hasConcept C2777129736 @default.
• W2171875475 hasConcept C2777832160 @default.
• W2171875475 hasConcept C2779185760 @default.
• W2171875475 hasConcept C2781069245 @default.
• W2171875475 hasConcept C71924100 @default.
• W2171875475 hasConceptScore W2171875475C126322002 @default.
• W2171875475 hasConceptScore W2171875475C142724271 @default.
• W2171875475 hasConceptScore W2171875475C1862650 @default.
• W2171875475 hasConceptScore W2171875475C204787440 @default.
• W2171875475 hasConceptScore W2171875475C27081682 @default.
• W2171875475 hasConceptScore W2171875475C2776042228 @default.

• next